Cholangiocarcinoma (bile duct cancer) · line 2 · Infigratinib monotherapy (CBGJ398X2204) — 2L+ FGFR2-fusion cholangiocarcinoma (HISTORICAL)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-INFIGRATINIB-CHOLANGIO-2L |
| ID | IND-CHOLANGIO-2L-INFIGRATINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | DIS-CHOLANGIOCARCINOMA |
| Sources | SRC-ESMO-BTC-2023 SRC-NCCN-HEPATOBILIARY |
Notes
HISTORICAL STUB — drug WITHDRAWN voluntarily Aug-Sep 2022 (Helsinn / QED Therapeutics; not a safety withdrawal). Retained for historical / comparator-trial completeness; render layer must NOT surface as active recommendation. Pivotal trial source (CBGJ398X2204, Javle JCO 2018 + Lancet Gastroenterol Hepatol 2021) NOT yet authored in KB — cited via SRC-NCCN-HEPATOBILIARY + SRC-ESMO-BTC-2023; flag for source-ingest follow-up. Pending Clinical Co-Lead sign-off. Pairs with IND-CHOLANGIO-2L-FGFR2-FUSION-PEMIGATINIB and IND-CHOLANGIO-2L-FUTIBATINIB.
Used By
Indication
IND-CHOLANGIO-2L-FUTIBATINIB- IND-CHOLANGIO-2L-FUTIBATINIB